Effect of Steroids on Gd-Enhancing Lesions Before & During Beta Interferon 1a Trtm in Relapsing Remitting MS
Neurol 50:403-406, Gasperini,C.,et al, 1998
Interferon Treatment for Multiple Sclerosis:Autoimmune Complications May be Lethal
Neurol 50:570-571, Durelli,L.,et al, 1998
Treatment of Postural Hypotension
JNNP 65:285-289, Mathias,C.J.&Kimber,J.R., 1998
Depression, Palpitations, and Unilateral Pulsatile Tinnitus Due to a Dopamine-Secreting Glomus Jugulare Tumor
Am J Med 104:310-311, Troughton,R.W.,et al, 1998
Rate of Pregnancy-Related Relapse in Multiple Sclerosis
NEJM 339:285-291, 3391998., Confavreux,C.,et al, 1998
Synergistic Immunomod Effects of Interferon-Beta1b & Phosphodiesterase Inhib Pentoxifylline in Pts with Relapsing-Remit MS
Ann Neurol 44:27-34, 71998., Weber,F.,et al, 1998
Longitudinal Study of CSF Levels of Tau, A beta 1-40, and A beta 1-42 (43) in Alzheimer's Disease
Ann Neurol 44:17-26, 61998., Kanai,M.,et al, 1998
Low-Dose Steroids Reduce Flu-Like Symptoms at the Initiation of INFB-1b in Relapsing-Remitting MS
Neurol 50:1910-1912, Rio,J.,et al, 1998
Incidence and Significance of Neutralizing Antibodies to Interferon Beta-1a in Multiple Sclerosis
Neurol 50:1266-1272, 12061998., Rudick,R.A.,et al, 1998
Migrainous Visual Accompaniments are not Rare in Late Life:The Framingham Study
Stroke 29:1539-1543, Wijman,C.A.C.,et al, 1998
Interferon B Therapy for Multiple Sclerosis
Lancet 352:1486-1487, Goodkin,D.E., 1998
Interferons in the Treatment of Multiple Sclerosis,Do They Prevent the Progression of the Disease?
Arch Neurol 55:1578-1580,1583, Rice,G.&Ebers,G, 1998
Interferons Should be Used to Treat Most Patients with MS
Arch Neurol 55:1581-1583, Herndon,R.M.&Jacobs,L, 1998
Randomised Double-Blind Placebo-Controlled Study of Interferon B-1a in Relapsing/Remitting Multiple Sclerosis
Lancet 352:1498-1504,1486, PRISMS, 1998
Placebo-Controlled Multicentre Randomised Trial of Interferon B-1b in Treatment of Secondary Progressive Multiple Sclerosis
Lancet 352:1491-1497,1486, European Study Group on Interferon B-1b in Seconda, 1998
The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
High-Density Lipoprotein Cholesterol & Risk of Ischemic Stroke Mortality:21-Yr FU of 8586 Men-Israeli Ischemic Heart Dis Study
Stroke 28:83-87, Tanne,D.,et al, 1997
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Character of MRI Response to Trtm with Interferon Beta-1B:Enhancing MRI Lesion Freq as Prim Outcome Measure
Neurol 49:862-869, Stone,L.A.,et al, 1997
Impact of Interferon Beta-1A On Neurologic Disability in Relapsing Multiple Sclerosis
Neurol 49:358-363, Rudick,R.A.,et al, 1997
A Comparison of Divalproex with Propranolol and Placebo for the Prophylaxis of Migraine Without Aura
Arch Neurol 54:1141-1145, Kaniecki,R.G., 1997
Electromagnetic Field Exposure May Cause Increased Production of Amyloid Beta & Eventually lead to Alzheimer's Disease
Neurol 47:1594-1600, Sobel,E.&Davanipour,Z., 1996
Neutralizing Antibodies During Treatment of Multiple Sclerosis with Interferon Beta-1b
IFNB MS Study Group & UBC MS. MRI Analysis Group, Neurol 47:889-8946., , 1996
Guidelines for Physicians with Patients on IFNB-1b:The Use of an Assay for Neutralizing Antibodies (NAB)
Neurol 47:865-866, Paty,D.,et al, 1996
Interferon Beta in Multiple Sclerosis
BMJ 313:1159, 1157, 1195996., Richards,R.G., 1996
Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996
Side Effect Profile of Interferon Beta-1b in MS:Results of an Open Label Trial
Neurol 46:552-554, Neilley,L.K.,et al, 1996
Lipids and Stroke
Arch Neurol 53:303-308, Hachinski,V.,et al, 1996
Clinicopath Conf
Tangier Disease, Case 16-1996, NEJM 334:1389-1394996., , 1996
Image Analysis of B-Amyloid Load in Alzheimer's Disease and Relation to Dementia Severity
Lancet 346:1524-1528, Cummings,B.J.&Cotman,C.W., 1995
Apolipoprotein E, Dementia, and Cortical Deposition of B-Amyloid Protein
NEJM 333:1242-1247, 12831995., Polvikoski,T.,et al, 1995
Is Neurally Mediated Hypotension an Unrecognized Cause of Chronic Fatigue?
Lancet 345:623-624, Rowe,P.C.,et al, 1995
Severe Necrotizing Cutaneous Lesions Complicating Treatment with Interferon Beta-1b
NEJM 332:1584, Sheremata,W.A.,et al, 1995
The Interferons:Biological Effects, Mechanisms of Action, and Use in Multiple Sclerosis
Ann Neurol 37:7-15, Weinstock-Guttman,B.,et al, 1995
Management of the Behavioral Manifestations of Dementia
Arch Int Med 155:250-260, Yeager,B.F.,et al, 1995
Drugs for Migraine
The Medical Letter 37:17-20, , 1995
Vitamin C and Risk of Death from Stroke and Coronary Heart Disease in Cohort of Elderly People
BMJ 310:1563-1566, 15481995., Gale,G.R.,et al, 1995
Lipoprotein (a) & Asympt Carotid Art Disease:Evidence of a Prominent Role in the Evol of Advanced Carotid Plaques
Stroke 26:1582-1587, Willeit,J.,et al, 1995
Plasma Concentration of Lipoprotein (a) and the Risk of Future Stroke
JAMA 273:1269-1273, Ridker,P.M.,et al, 1995
Interferon Beta-1b in the Trtm of MS:Outcome of the Randomized Controlled Trial
IFNB Study Gr, Neurol 45:1277-12851995., , 1995
Effect of Interferon-B on Blood-Brain Barrier Disrupt Demonst by Contrast MRI in Relapsing-Remitting MS
Ann Neurol 37:611-619, Stone,L.A.,et al, 1995
Betaseron for Multiple Sclerosis:Implications for Therapeutics
Arch Neurol 51:125-128, Rudick,R., 1994
Tilt-Talbe Testing and Oral Metoprolol Therapy in Young Patients with Unexplained Syncope
pediatrics 93:278-283, O'Marcaigh,A.S.,et al, 1994
The Prolonged QT Syndrome Presenting as Epilepsy:A Report of Two Cases and Literature Review
Neurol 44:1408-1410, Pacia,S.V.,et al, 1994
Practice Advisory on Selection of Patients with Multiple Sclerosis for Treatment with Betaseron
Neurol 44:1537-1540, Alter,M.,et al, 1994
Are Magnetic Resonance Findings Pred of Clinical Outcome in Therapeutic Trials in MS? The Dilemma of Interferon-B
Ann Neurol 36:14-18, McDonald,W.I.,et al, 1994
The Relationship of Essential Tremor to Other Movement Disorders:Report on 678 Patients
Ann Neurol 35, 717-7231994., Koller,W.C.,et al, 1994
Human Prion Diseases
Ann Neurol 35:385-395, Prusiner,S.B.&Hsiao,K.K., 1994
Parkinsonism Unmasked by Verapamil
Clinical Neuropharmacol 16:263-265, Garcia-Albea,E.,et al, 1993